Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

ERGO is launching ALERRT, a multi-disciplinary consortium building a patient-centered clinical research network to respond to epidemics across sub-Saharan Africa.

ALERRT aims to reduce the public health and socio-economic impact of disease outbreaks in sub-Saharan Africa by building a sustainable clinical and laboratory research preparedness and response network.

Read the full article

Similar stories

Oxford’s RECOVERY trial team amongst MRC‘s Outstanding Team Impact prize finalists

The inaugural MRC Impact Prize recognises teams who have made outstanding impacts in health and medical research. The winners will be announced at a ceremony in the spring.

Constant genetic surveillance needed to counter multidrug-resistant malaria strains

Continual monitoring of genetic changes in parasite populations is a powerful tool for analysing malaria outbreaks and identifying emerging multidrug-resistant malaria strains, say researchers from NDM’s Mahidol-Oxford Tropical Medicine Research Unit (MORU).

Lancet study informs WHO guidelines for the treatment of malaria in pregnancy

The study from the Worldwide Antimalarial Resistance Network (WWARN) provides compelling evidence that artemether-lumefantrine should now replace quinine as the treatment of choice in the first trimester.

Leedham Lab receives funding to improve bowel cancer treatments

The Leedham Lab at the Wellcome Centre for Human Genetics in the Nuffield Department of Medicine (NDM) has been awarded over £2m from Cancer Research UK to develop a new tool that could help guide how bowel cancer patients are treated in the future.

Oxford’s Ebola vaccine recommended for deployment against Uganda outbreak

A vaccine developed by the Oxford Vaccine Group’s Prof Teresa Lambe and supported in clinical trials and manufacture scale-up by researchers from Nuffield Department of Medicine's Jenner Institute has been recommended for inclusion in a ring vaccination trial to combat a Sudan ebolavirus outbreak in Uganda.

New study provides important insights into TB correlates of protection

Researchers from the Nuffield Department of Medicine’s Jenner Institute have today reported the findings from a study investigating whether previously identified correlates of protection associated with the risk of tuberculosis (TB) disease could also be associated with the risk of infection from the bacteria that causes TB.